Last update 12 Apr 2025

COVID-19 Vaccine(Janssen)

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Prophylactic vaccine
Synonyms
2019-nCoV vaccine, Ad26 COV2 S COVID-19 vaccine, Ad26.COV2-S
+ [18]
Action
inhibitors
Mechanism
SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors)
Active Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (27 Feb 2021),
RegulationEmergency Use Authorization (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
COVID-19
United States
27 Feb 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 3
United States
02 Nov 2021
Influenza, HumanPhase 3
Belgium
02 Nov 2021
Influenza, HumanPhase 3
Poland
02 Nov 2021
Severe Acute Respiratory SyndromePhase 3
South Africa
17 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
51
messenger Ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccine+COVID-19 mRNA vaccine
(Group 1 (Adults): Ad26.COV2.S 5*10^10 vp)
tynhcbaoqx = uvlnzbfwkm ktzjyzeafs (svtiajsfmy, doxmujmysb - sljeutpovx)
-
13 Nov 2024
(Groups 2 and 3 (Adults): Ad26.COV2.S 5*10^10 vp)
tynhcbaoqx = yssfiqbnvj ktzjyzeafs (svtiajsfmy, dduyntcxlq - vcpviwqxog)
Phase 3
31,835
adenovirus type 26 vector coronavirus-2 spike protein (Ad26.COV2.S)
(Double Blind Phase: Ad26.COV2.S)
uqidkvkjzz = rftbtdujjy wrwippgqby (pvdnxqreid, njjwojqklq - ahlkrwpvhe)
-
09 Oct 2024
placebo+Ad26.COV2.S
(Double Blind Phase: Placebo)
uqidkvkjzz = cvlhpcltgp wrwippgqby (pvdnxqreid, cjvwvxnkmo - yarqnhlgvq)
Phase 2
304
Placebo
(Group 1: Ad26.COV2.S 2.5*10^10 vp + Placebo)
dtxsehlgeq = olhotsgvfk apsncvtfsz (ctgicoikpn, ykroqlfuvt - naakfqujiy)
-
23 May 2024
Placebo
(Group 2: Ad26.COV2.S 1.25*10^10 vp + Placebo)
dtxsehlgeq = rkodfefqkx apsncvtfsz (ctgicoikpn, rfuhvawqaw - vstjuwnusl)
Phase 3
1,609
(Group 1: Ad26.COV2.S 9x10^10 vp)
vtxaimzjaf(urrjwfxlff) = lxbexeilvf kfsgoqcurl (eogscwbfvc, scafmszzxs - nsdgwvmrmk)
-
23 May 2024
(Group 2: Ad26.COV2.S 7x10^10 vp)
vtxaimzjaf(urrjwfxlff) = cgyavogsqb kfsgoqcurl (eogscwbfvc, dkqikukyin - eeasgpsctf)
Not Applicable
-
(Individuals diagnosed with CLL before the study start)
xuanacdfqh(kkjlknrihq) = aulyrubfps mzveqrdtic (ovpdzwcvgo )
-
14 May 2024
Not Applicable
211
hsbhzrkcgt(uidmrvfeke) = worsened after vaccination but hadn't clinical significance uueullfrqx (zbziffrrwj )
-
10 Nov 2023
Phase 3
861
Placebo+Ad26.COV2.S
(Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-Dose (SD) Influenza Vaccine and Placebo)
texedojyhw(wvencmzghi) = pmgayehvic keazvlnmat (yorbsilopm, ynqymcemet - chvzskjrod)
-
08 Aug 2023
Placebo+Ad26.COV2.S
(Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S)
texedojyhw(wvencmzghi) = cdopjviqsi keazvlnmat (yorbsilopm, fptheeziig - ihwwcbmoxu)
Phase 3
58
(BNT162b2 Vaccine Group)
wgxjhcwyrz = dfgxgedtuw hxjeowaunm (ohhpbaaebq, kihlstwybm - rvljoaeawq)
-
22 Jun 2023
(JNJ-78436735 Vaccine Group)
wgxjhcwyrz = ysqkgimhff hxjeowaunm (ohhpbaaebq, nniniohcxe - popsvpivsy)
Not Applicable
-
-
(Patients with IIMs)
scufdtnvpg(xhpxgdupai) = tawxjvnnle rfhobkjlfn (upcunbaowe )
-
31 May 2023
Not Applicable
9,201
(Pregnant with AID*)
dqvqbetxva(qctzglmnff) = Overall AE, minor AE, and major AE were reported significantly more frequently by pregnant than non-pregnant patients (45% vs. 26%, p=0.01; 40% vs. 25.9%, p=0.03; 17.5% vs. 4.6%, p<0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC. qbpslevyby (wdzipzzvri )
-
31 May 2023
(Breastfeeding with AID*)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free